Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 19, 2007 Brian Lawler	Victory for Sanofi and Bristol-Myers The pharmaceutical gains a crucial legal victory for its top compound. Investors, take note.
The Motley Fool September 1, 2006 Brian Lawler	Bristol-Myers and Sanofi Get Apotex to Stop A temporary injunction against generic drug manufacturer Apotex over patents involving Plavix means big news for all the companies involved.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool April 10, 2007 Brian Lawler	Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs.
The Motley Fool May 1, 2007 Brian Lawler	Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note.
The Motley Fool October 30, 2006 Brian Lawler	Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	Bristol-Myers Blames the Generic Again The fourth quarter's financial results are dominated by generic competition.
The Motley Fool October 31, 2007 Brian Lawler	Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool May 7, 2007 Brian Lawler	Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker.
The Motley Fool July 30, 2007 Brian Lawler	Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool May 28, 2008 Brian Lawler	A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan.
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool July 31, 2006 Stephen D. Simpson	More Plavix Headaches for Bristol-Myers Problems with a Plavix settlement put a large chunk of earnings at risk. Investors, take note.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool December 3, 2008 Brian Orelli	High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool February 28, 2007 Brian Lawler	Bristol-Myers Stays Out of Trouble A federal monitor finds Bristol-Myers does not have to pay up over a questionable business deal.
The Motley Fool July 28, 2005 Stephen D. Simpson	Bristol-Myers' Road to Better Health Bristol-Myers looks toward 2007 and a resumption of real growth. For now, things could be a lot worse. At least investors can't say they're not getting paid to be patient.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.
The Motley Fool June 8, 2007 Brian Lawler	Lilliputian Attack on Lilly? While every investor should have some degree of exposure to pharmaceutical stocks, recent patent decisions in two of the biggest pharmaceutical drugs markets should serve as a warning of the potential litigation dangers when investing in some of the sector's giants.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
The Motley Fool June 6, 2008 Brian Lawler	Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects.
The Motley Fool August 31, 2009 Brian Orelli	Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way.
BusinessWeek October 25, 2004 Gene G. Marcial	Par: Out Of The Rough? Since posting disappointing earnings in April, Par Pharmaceutical, No. 6 in U.S. generic drugs, has seen its shares plummet from 61 to 34.
The Motley Fool January 19, 2007 Karl Thiel	The Best Drug Stock for 2007: Momenta Investors, swing for the fences with this drug company.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.